Shop the Money & Markets Store
Are you a finance, investing, economics or accounting professional? Find books, read blog posts, and discover new authors and thought-leaders in Money & Markets, a new home for finance industry professionals on Amazon.com. > Shop now
Joe Duarte M.D.,www.joe-duarte.com, is a widely read analyst and writer. His daily Market IQ column is read by thousands of investors, information seekers, and intelligence aficionados and professionals around the world.
Dr. Duarte is is well recognized as a geopolitical and financial market analyst combining a unique set of viewpoints into an original blend of solutions for his audience.
He is author of "Trading Futures for Dummies," "Market Timing for Dummies" "Futures and Options for Dummies," "Successful Energy Sector Investing," "Successful Biotech Investing," and co author of 'After-Hours Trading Made Easy.
He is a board certified anesthesiologist, a former registered investment advisor, and former President of River Willow Capital Management.
Dr. Duarte has appeared on CNBC and looged weekly on the Financial Sense Newshour with Jim Puplava radio show for many years, where he commented on the Energy markets and geopolitics. He has logged appearances on Biz Radio, Wall Street Radio, JagFn, WebFN, KNX radio in Los Angeles, and WOWO radio.
One of CNBC's original Market Mavens, Dr. Duarte has been writing about the financial markets since 1990. An expert in health care and biotechnology stocks, the energy sector, as well as financial market sentiment, his daily syndicated stock columns have appeared on leading financial web sites, including Reuter's e-charts, afterhourtrades.com and MarketMavens.com.
His articles and commentary have been featured Marketwatch.com. He has appeared in Barron's, U.S.A. Today, Smart Money, Medical Economics, and in Technical Analysis of Stocks and Commodities magazines.
Dr. Duarte published the critically acclaimed market timing newsletter 'The Wall Street Detective,' from 1990-1998, when it became an exclusively electronic publication.
His daily market commentary 'Joe Knows' appeared on Financialweb.com from 1998-2000.
Dr. Duarte served as senior columnist for investorlinks.com from 1998-2001.
This book is not just about biotech investing. Duarte, a technical analyst as well as a physician uses biotechs as a model for approaching the market. The book has all the shortcomings other reviewers warn you of: it's painfully redundant, incomplete and simplistic. But it does offer a consistent approach to stock investing IF you supplement it with other material. It also lists some neat web sites.
Dr. Duarte is an anesthesiologist, a professional stock commentator and an investment advisor. In this book he seeks to "bring stock picking and science together." The book gives you a basic scientific background of the biotechnology industry, describes the way that the industry is regulated in creating new drugs, profiles the leading pharmaceutical and biotechnology companies, proposes a way to evaluate the fundamental performance of each company, and describes the ways that you can use technical analysis to pick when to buy and sell these stocks. This helpful information is provided against the context of the wild swings in stock prices as the overall market and general news move stock price levels. He begins by pointing out that the statement by President Clinton and Prime Minister Blair that the rights of biotechnology companies should be restricted was a short-term storm, but a long-term non-event. Such moments provide buying opportunities. The book has two basic weaknesses. First, it fails to point out that most people should avoid biotechnology stocks. They should be very volatile, and can have stomach-churning drops that will cause many investors to sell at the worst times. The vast majority of ordinary investors should be buying broad-based index funds (see Common Sense on Mutual Funds). Second, the book fails to point out that the rate of discoveries in any given company should be slowing down in the future. This is because after a company is public, it will usually limit R & D to try to create a profit track record and because the science is simply more difficult and lengthy as more proteins and enzymes become involved in solutions. As a result, we could see very long time periods when investments will be under water.Read more ›
This book is far too basic for anyone who graduated high school biology. It is redundant, condecending, and very poorly edited. Duarte's explanations of scientific/ medical concepts are painfully dumbed down. (Admitedly, I too I am a physician, but I think anyone with even a remote scientific background would agree.)Worse yet, much of the book is composed of generic and dated summaries of the major biopharma companies (not even an appropriate use of paper in the age of [investment websites]I was hoping to learn from this book fundamental priniciples for evaluating biotechnolgy companies from a seasoned wall street/ medicine hybrid. But Duarte gives too much general investement advice, and too little advice specific to biotechnology investing...